Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination.

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Medtronic (MDT) beat estimates for profits in the last quarter thanks to strong demand for diabetes and heart devices. Earnings per share of $1.39 increased 7% on last year in the Fiscal 2025 ...

Novo Nordisk has teamed up with Medtronic to provide integrated digital solutions for people with diabetes, allowing dosing data from the Danish pharma’s insulin pens to be shared with the US ...

Successfully incorporating AI into future products will fulfil Medtronic’s mission of using biomedical engineering to restore health and reduce the management burden for people with diabetes.

Medtronic's surgical device sales decline due to inventory issues CEO Martha monitors impact of Trump's tariffs Shares down more than 7% in morning trade Feb 18 (Reuters) - Medtronic (MDT.N ...